Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor
about
P1343
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational ModificationsStructure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopesPhenotypes of allo- and autoimmune antibody responses to FVIII characterized by surface plasmon resonanceHigh-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance.Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model.Designed ankyrin repeat proteins: a new approach to mimic complex antigens for diagnostic purposes?Six amino acid residues in a 1200 Å2 interface mediate binding of factor VIII to an IgG4κ inhibitory antibody.The 1.7 Å X-ray crystal structure of the porcine factor VIII C2 domain and binding analysis to anti-human C2 domain antibodies and phospholipid surfacesEffect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo.The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.Conservative mutations in the C2 domains of factor VIII and factor V alter phospholipid binding and cofactor activity.Functional factor VIII made with von Willebrand factor at high levels in transgenic milkA major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function.Structure of the Human Factor VIII C2 Domain in Complex with the 3E6 Inhibitory Antibody.Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation.Characterization and solution structure of the factor VIII C2 domain in a ternary complex with classical and non-classical inhibitor antibodies.Membrane-binding properties of the Factor VIII C2 domain.Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivoEpitope mapping of inhibitory antibodies targeting the C2 domain of coagulation factor VIII by hydrogen-deuterium exchange mass spectrometry.Engineering less immunogenic and antigenic FVIII proteins.Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition.Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va.Secretory signal peptide modification for optimized antibody-fragment expression-secretion in Leishmania tarentolae.
P2860
Q26738810-4416039B-7FD2-48B2-96A3-A3D426CCF512Q27680123-4D719934-EB03-4060-942E-7C87E11EE650Q28487777-E0696CAA-2876-4C75-87F0-E13A401088FEQ30577011-43D34788-00A6-4AA0-9F52-AF70570F4695Q33962546-1C49E401-8E20-4DC5-A7CA-C3F5B7E50CD0Q34692067-EC0C2A9E-9B18-432E-A7E0-D9087199E022Q35007278-F3503908-C11D-4B50-B77A-E2E100BEC236Q35578480-63E4C1F2-0D09-4800-96D5-64B4506F00D7Q35782984-86DA2DA6-3FEB-4A92-BE43-FA9FC450BF16Q35832756-FB7C8D6E-59DD-47F6-86B4-AF2EF3AFF9E9Q36206445-F1258F5A-0F0D-455D-822A-1632E4595F18Q36239576-09EACD1C-D0AE-4B9A-AA93-191A5D842058Q36250957-9BD0399C-6CAD-4A89-843E-053C6AF24EB3Q36310238-C412DE86-51F9-4521-A565-6DCFED9B7CD4Q36447889-ED1D4132-D4DD-4EED-8401-F32750D2006AQ36742268-4376D9C8-8ED1-4805-98EA-CA4118E812EAQ36896861-CEB04972-77A1-417D-8A02-57553D547A12Q36897565-7D459C17-913E-4420-A54E-58D93DD2F4C8Q37626483-81E924CB-F158-453D-BB39-C6DE284A4AA7Q38632876-6F2C6029-39B6-4A10-BAB6-33719C9891A2Q39600375-3118EFE3-73BB-450C-AB53-5D23B65146DCQ41665286-0F006234-3B3D-4AB9-8042-0A7378E4FDEAQ41771533-10C22281-BC63-44D5-BBAD-81AB063545E0Q42063113-5AD39A75-8D31-4C67-8D7F-5AC454DE5DCC
P2860
Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor
description
1998 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1998
@ast
im Juli 1998 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1998/07/15)
@sk
vědecký článek publikovaný v roce 1998
@cs
wetenschappelijk artikel (gepubliceerd op 1998/07/15)
@nl
наукова стаття, опублікована в липні 1998
@uk
научни чланак (објављен 1998/07/15)
@sr
name
Mechanism and kinetics of fact ...... hilia A patient with inhibitor
@ast
Mechanism and kinetics of fact ...... hilia A patient with inhibitor
@en
Mechanism and kinetics of fact ...... hilia A patient with inhibitor
@nl
type
label
Mechanism and kinetics of fact ...... hilia A patient with inhibitor
@ast
Mechanism and kinetics of fact ...... hilia A patient with inhibitor
@en
Mechanism and kinetics of fact ...... hilia A patient with inhibitor
@nl
prefLabel
Mechanism and kinetics of fact ...... hilia A patient with inhibitor
@ast
Mechanism and kinetics of fact ...... hilia A patient with inhibitor
@en
Mechanism and kinetics of fact ...... hilia A patient with inhibitor
@nl
P2093
P921
P3181
P1433
P1476
Mechanism and kinetics of fact ...... hilia A patient with inhibitor
@en
P2093
A. Benhida
B. G. Desqueper
J. G. Gilles
J. M. Saint-Remy
J. Vermylen
K. Peerlinck
K. Thielemans
L. Vander Elst
P304
P3181
P407
P4510
P577
1998-07-15T00:00:00Z